KRAS and non-small cell lung carcinoma: For KRAS G12C-mutant CRCs (n = 45), the ORR was 22%, with a DCR of 87%, a median DoR of 4.2 months, and a median PFS of 5.6 months.221 Compared with docetaxel, adagrasib was evaluated more recently in a phase III trial (KRYSTAL-12) in 301 patients with KRASG12C advanced NSCLC who progressed after platinum-based chemotherapy and an ICI.226 In this trial, patients were randomized 2:1 (to receive adagrasib), and at a median follow-up time of 9.4 months, the primary endpoint PFS was significantly improved (HR: 0.59; 95% CI: 0.45–0.76; p < 0.0001), with a median PFS of 5.49 vs. 3.84 months.